Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates target attainment after either intermittent intravenous bolus or intravenous continuous infusion of cefotaxime in critically ill patients. Critically ill patients will be randomized to intermittent infusion or continuous infusion of cefotaxime.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Center Groningen
• Treatments: Cefotaxime; Cefoxitin

Criteria

Inclusion Criteria:

• Admitted to intensive care

• Able to give informed consent by themselves or informed consent can be obtained via next of kin

• Indication for treatment with cefotaxime (as judged by treating physician) in the context of our standard treatment protocol of Selective decontamination of the digestive tract (SDD).

Exclusion Criteria:

• Renal replacement therapy

• Contra-indication for cefotaxime, including known or suspected allergy to cefotaxime

• No indication for an arterial line; an arterial line will not be placed solely for the purpose of this study; thus, only patients with an indication for an arterial line outside this protocol are eligible.